LRI Investments’s Supernus Pharmaceuticals SUPN Stock Holding History

LRI Investments’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$47	Buy	+1	New	+$48	﹤0.01%	1905

Other funds holding SUPN

SIMG

Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

PFC

Phocas Financial Corp Alameda, California $721M AUM 63.77% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return

LRI Investments's SUPN Position: Q2 2026 in Review

LRI Investments opened a new position in Supernus Pharmaceuticals (SUPN) in Q2 2026: 1 share worth $47. The stake represents ﹤0.01% of the portfolio and ranks #1905 among its holdings.

84 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

LRI Investments held 1 share of Supernus Pharmaceuticals worth $47 as of Q2 2026.
Supernus Pharmaceuticals was a new LRI Investments position in Q2 2026.
Supernus Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1905 holding.
84 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.